HLA

TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity

Retrieved on: 
Lunedì, Novembre 1, 2021
Research, Cancer, Security (finance), U.S. Securities and Exchange Commission, Patient, CGMP, Private Securities Litigation Reform Act, Cell, Review, HLA, Annual report, Risk, Clinical trial, TCR, Gene, Truc, Nasdaq, Therapy, GLOBE, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced today the expansion of its manufacturing capacity by exercising an option on a second clean room at ElevateBio BaseCamp which adds to the buildout of clinical and commercial supply currently underway at its Rockville, MD, facility.

Key Points: 
  • The long-term focus for TCR2 clinical and commercial supply remains on developing the 85,000 square foot Rockville facility as its manufacturing center of excellence in the U.S.
  • In connection with this expansion, TCR2 proposes to cease manufacturing activities at the Cell and Gene Therapy Catapult (CGT Catapult) in Stevenage, UK.
  • This increase in cGMP manufacturing capacity at ElevateBio BaseCamp will ensure we are able to execute on the gavo-cel Phase 2 trial and the clinical plans for our next-generation TRuC-T cell products, said Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics.
  • The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA).

A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021

Retrieved on: 
Lunedì, Novembre 1, 2021
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Annual general meeting, MD, 2021 Essex County Council election, Technology, NCT, Neoplasm, Immunotherapy, Patient, Section 32, Walter, CGMP, HLA, LOH, Precision medicine, Washington Convention Center, MSLN, The Society, CEA, StepStone Group, Doctor of Philosophy, Regent, SITC, Observational study, Pharmaceutical industry, Medical imaging

A2 Biotherapeutics , Inc., A2 Bio, is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors.

Key Points: 
  • A2 Biotherapeutics , Inc., A2 Bio, is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors.
  • A2 Bio will make two presentations at The Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting taking place virtually and in person on Nov. 1014, 2021 at the Walter E. Washington Convention Center in Washington, D.C.
  • The first presentation will focus on new preclinical in vitro and in vivo demonstrations of both CEA (A2B530) and MSLN (A2B694) Tmod T cell therapy.
  • Julian Molina, MD, PhD, Professor of Oncology, Mayo Clinic, Rochester MN states, BASECAMP-1 is a premier example of precision medicine.

Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

Retrieved on: 
Giovedì, Ottobre 28, 2021
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Biology, ATRA, LinkedIn, Cancer, Twitter, Patient, Investor, Canadian Aviation Regulations, Lymphatic system, Multiple sclerosis, Epstein–Barr virus, ID, Hematological Cancer Research Investment and Education Act, HLA, Degenerative disease, Northwest Biotherapeutics, TCR, Company, Media, Autoimmune disease, Webcast, EDT, Nasdaq, EBV, Antigen, Vaccine

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.
  • Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EDT to discuss the Companys financial results and provide a corporate update.
  • Analysts and investors can participate in the conference call by dialing 888-437-3179 for domestic callers and 862-298-0702 for international callers, using the conference ID 13723551.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Aston Sci. Announces the Study Results of Two Therapeutic Cancer Vaccines at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Mercoledì, Ottobre 27, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Aston, Safety, Geriatrics, Breast cancer, Research, Peptide, Recurrence, Diagnosis, Technology, Cancer, Disease, Industry, Immunotherapy, NH Investment & Securities, Immunology, Patient, KOSDAQ, Society, Ministry, HSP90, HLA, Clinical trial, CEO, Epitope, IND, American Society of Clinical Oncology, SITC, Ministry of Food and Drug Safety, ASCO, Pharmaceutical industry

Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November.

Key Points: 
  • Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November.
  • At the 2021 American Society of Clinical Oncology (ASCO) in June, Aston Sci.
  • demonstrated the medical efficacy and long-term safety of AST-301 through the results from phase 1 clinical trials on 66 patients with HER2-positive advanced breast cancer.
  • AST-301 is currently under IND review by the Ministry of Food and Drug Safety for subsequent clinical trials.

Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

Retrieved on: 
Martedì, Ottobre 26, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Method, MD, Peptide, Immunotherapy, Efficiency, SVP, College of American Pathologists, Allele, Cancer, Veterans' affairs, College, Clinical Laboratory Improvement Amendments, Genomics, Molecular & Cellular Proteomics, PSNL, Twitter, U.S. Securities and Exchange Commission, Leadership, HLA, SHERPA, Biomarker, COVID-19, Growth, Systematic, MHC, Nasdaq, Proteomics, Immune system, Veteran, CMO, Medical imaging

To improve performance and generalizability, SHERPA was trained with immunopeptidomics data from newly engineered cell lines mono-allelic for HLA combined with other publicly available datasets.

Key Points: 
  • To improve performance and generalizability, SHERPA was trained with immunopeptidomics data from newly engineered cell lines mono-allelic for HLA combined with other publicly available datasets.
  • In addition, SHERPA was designed to more comprehensively capture epitope binding and presentation features to further enhance the predictive power of the algorithm.
  • Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer and population sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.

TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors

Retrieved on: 
Lunedì, Ottobre 25, 2021
Safety, Research, NSCLC, Cancer, Ipilimumab, BMY, Bristol Myers Squibb, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, MPM, Large-cell lung carcinoma, Ovarian cancer, NYSE, Review, HLA, Adult, Annual report, Risk, Cholangiocarcinoma, Clinical trial, TCR, Cell, Truc, Nasdaq, Therapy, Mesothelioma, GLOBE, Pharmaceutical industry

We are very pleased to establish a collaboration agreement with Bristol Myers Squibb for our Phase 2 clinical trial as this enables us to evaluate the potential synergy between gavo-cel and immune checkpoint inhibitors, said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.

Key Points: 
  • We are very pleased to establish a collaboration agreement with Bristol Myers Squibb for our Phase 2 clinical trial as this enables us to evaluate the potential synergy between gavo-cel and immune checkpoint inhibitors, said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.
  • We look forward to determining whether gavo-cel can provide additional clinical benefit to these patients.
  • The planned Phase 2 clinical trial will evaluate the antitumor activity and better characterize the safety of gavo-cel at the selected recommended Phase 2 dose (RP2D).
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

Retrieved on: 
Mercoledì, Ottobre 20, 2021
Acute lymphoblastic leukemia, Toxic shock syndrome, CD70, Clinical trial, IND, TCR, Risk, Renal cell carcinoma, Cell, Private Securities Litigation Reform Act, COVID-19, U.S. Securities and Exchange Commission, Security (finance), Adult, Annual report, Webcast, Autoimmune disease, HLA, Investor, Nasdaq, R, Therapy, Company, GLOBE, Patient, Truc, Graft-versus-host disease, Degenerative disease, Population, Cancer, CRS, Cytokine, Marketing, Safety, CRISPR, Pharmaceutical industry, Vaccine

In addition, we will introduce compelling preclinical data for our TRuC Tregs, which could expand our footprint into the autoimmune disease setting.

Key Points: 
  • In addition, we will introduce compelling preclinical data for our TRuC Tregs, which could expand our footprint into the autoimmune disease setting.
  • TCR2 announced today the completion of the 3-patient cohort at the new dose level 3.5A (3x108/m2 following lymphodepletion) using a split dosing approach.
  • TCR2 Therapeutics will host a conference call and webcast on Wednesday, October 20 at 8:00am E.T.
  • The webcast and presentation will be made available on the TCR2 Therapeutics website in the Investors section under Events at investors.tcr2.com/events.

TCR² Therapeutics to Host R&D Day on October 20, 2021

Retrieved on: 
Mercoledì, Ottobre 13, 2021
Cell, Ovarian cancer, Lymphatic system, Nasdaq, Cancer, Aall, Acute lymphoblastic leukemia, NHL, Patient, Degenerative disease, GLOBE, NSCLC, Investor, HLA, TCR, Therapy, Cholangiocarcinoma, Vaccine

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m.
  • ET on Wednesday, October 20, 2021.
  • The meeting will feature updates on the Companys emerging oncology pipeline including enhancements, novel targets and allogeneic TRuCs as well as TRuC Tregs for autoimmune diseases.
  • Speakers will include:
    To register for the virtual event or watch a live webcast of the presentation, please visit the Investors page of the Companys website at investors.tcr2.com .

Versiti Launches HLA Loss of Heterozygosity Evaluation

Retrieved on: 
Martedì, Ottobre 12, 2021
Escape Room, Transplant, Method, Physician, Multimedia, VP, LOH, Health, Immunotherapy, Cancer, Human leukocyte antigen, Hematology, Zygosity, Flow cytometry, Partnership, HLA, Patient, Research, Transfusion medicine, Medical device, Dentistry

MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.

Key Points: 
  • MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.
  • Groundbreaking test helps detect and characterize genomic loss of heterozygosity in the HLA region.
  • Under the direction of Jennifer Schiller Ph.D., D(ABHI), the Versiti Histocompatibility Lab has created a comprehensive evaluation to detect genomic loss of heterozygosity specifically for transplant patients.
  • "We expect that our HLA Loss of Heterozygosity evaluation test will provide valuable information to physicians, enabling them to make better-informed decisions during post-transplant disease relapse, potentially giving patients better outcomes," said Dr. Matthew Anderson, VP and medical director, Versiti Diagnostic Laboratories.

OrganaBio Adds Perinatal and Adult Tissues for Clinical Manufacturing to its Portfolio of Products for Allogeneic Cell Therapy Development

Retrieved on: 
Venerdì, Ottobre 8, 2021
Stem Cells, Biotechnology, Baby, Maternity, Automotive, Health, Pharmaceutical, Oncology, General Automotive, Research, Consumer, Science, CGMP, Twitter, Adult, Corporate development, LLC, Stem cell, Hematology, CGTP, US, Multimedia, Program, LinkedIn, Health, NK, Industry, Research, Good tissue practice, Immunotherapy, RUO, Manufacturing, Head, CEO, Documentation, Therapy, Solution, HLA, Good manufacturing practice, Regenerative medicine, Macrophage, Process, IRB, Tissue, Fine chemical, Medical device

(Photo: OrganaBio, LLC)

Key Points: 
  • (Photo: OrganaBio, LLC)
    Each developer has custom supply and cell needs that must be met to achieve development milestones, clinical translation, and commercialization of life-saving cell-based cures.
  • OrganaBio meets these needs head-on by combining a proprietary supply chain of fresh tissue with in-house manufacturing capabilities.
  • OrganaBio has a proprietary tissue supply chain of perinatal and adult tissues and offers a range of starting cellular materials from these tissues.
  • OrganaBio manufactures off-the-shelf research grade products for allogeneic cell therapy development and is building cGMP manufacturing capabilities, with a forecasted launch in Q4 2021.